中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

57 records (took 0.021 seconds)

    42.
    发明专利
    未知

    公开(公告)号：NO20055616L

    公开(公告)日：2006-01-25

    申请号：NO20055616

    申请日：2005-11-28

    Applicant: BAXTER INT

    Inventor： KIPP JAMES E ,  WONG JOSEPH CHUNG TAK ,  DOTY MARK J ,  REBBECK CHRISTINE L ,  SUN CHONG-SON ,  PAPADOPOULOS PAVLOS ,  RABINOW BARRETT E ,  WHITE RANDY

    IPC: A61K9/14 ,  A61K9/50 ,  A61K9/51 ,  A61K31/496

    Abstract: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron-tomicron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 µm as measured by laser diffractonetry.

    EX-VIVO APPLICATION OF SOLID MICROPARTICULATE THERAPEUTIC AGENTS
    44.
    发明专利
    EX-VIVO APPLICATION OF SOLID MICROPARTICULATE THERAPEUTIC AGENTS 未知

    公开(公告)号：CA2565972A1

    公开(公告)日：2005-12-29

    申请号：CA2565972

    申请日：2005-06-08

    Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

    Inventor： KIPP JAMES E ,  RABINOW BARRETT E

    IPC: C12N5/06 ,  A61K9/14 ,  A61K35/12 ,  A61K45/00 ,  A61K47/48 ,  A61K49/00

    Abstract: The present invention is concerned with a method of preparing and delivering small particles of a pharmaceutically active material to a mammalian subject for treating diseases or disorders. A preferred embodiment entails: (i) the collection of tissue cells from an animal donor, (ii) selective or non-selective growth of these cells in a cell culture medium to which is added solid particles of a therapeutically active compound, mostly free of a drug carrier (about 10% or less, by weight), and having an average particle size of less than about 100 microns, (iii) contacting the cells in the cell culture medium with the solid particles of therapeutically active compound causing the particles to be taken up by the cells into either the intracellular compartment of the cultured cells, attachment of the active compound as particles to the periphery of such cells, or a combination of intracellular uptake and attachment to the cell surface, (iv) optionally, isolation and/or resuspension of the cells prepared in steps i through iii, (v) administering the cells to the mammalian subject. The pharmaceutically active material can be administered intravenously, intramuscularly, subcutaneously, intradermally, intra-articularly, intrathecally, epidurally, intracerebrally, via buccal route, rectally, topically, transdermally, orally, intranasally, via pulmonary route, intraperitoneally, or combinations thereof. After administration, the loaded cells transport the pharmaceutical composition as particles.

    Method for preparing submicron particles of paclitaxel
    48.
    发明专利
    Method for preparing submicron particles of paclitaxel 未知

    公开(公告)号：NZ546439A

    公开(公告)日：2010-04-30

    申请号：NZ54643904

    申请日：2004-11-03

    Applicant: BAXTER INT

    Inventor： CHAUBAL MAHESH ,  WERLING JANE ,  RABINOW BARRETT E

    IPC: A61K31/337 ,  A61K9/10 ,  A61K9/127 ,  A61K9/133 ,  A61K9/14 ,  A61K9/16 ,  A61K31/12 ,  A61K31/495 ,  A61K31/496 ,  A61K31/55 ,  A61K31/573

    Abstract: Disclosed is a method for preparing a pharmaceutical composition of submicron particles of precipitated paclitaxel or its derivative compounds, the solubility of which is greater in a water miscible first solvent than in a second solvent that is aqueous, the method comprising the steps of: (i) mixing into the water-miscible first solvent or the second solvent or both the water miscible first solvent and the second solvent, a first surface modifier comprising a phospholipid conjugated with a water-soluble or hydrophilic polymer; (ii) mixing into the water-miscible first solvent or the second solvent or both the water miscible first solvent and the second solvent, a second surface modifier selected from the group consisting of: anionic surfactants, cationic surfactants, non ionic surfactants and surface active biological modifiers; (iii) dissolving paclitaxel or its derivative compounds in the water-miscible first solvent to form a solution; (iv) mixing the solution with the second solvent to define a pre-suspension of particles; and (v) homogenizing the pre-suspension to form a suspension of precipitated small particles having an average effective particle size of less than about 1000 nanometres. Also disclosed is a composition of submicron particles of precipitated paclitaxel or its derivative compounds prepared by said method.

    High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
    49.
    发明专利
    High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products 未知

    公开(公告)号：NZ545744A

    公开(公告)日：2009-12-24

    申请号：NZ54574404

    申请日：2004-09-22

    Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

    Inventor： RODRIGUEZ ALFREDO ,  RABINOW BARRETT E ,  DOTY MARK ,  KONKEL JAMIE

    IPC: A61L2/00 ,  A61L2/02 ,  A61L2/04 ,  B65B55/02

    Abstract: A method for sterilizing a dynamic dispersion system is disclosed, wherein the method comprises the steps of: pressurizing a dispersion system of small particles or droplets to a pressure in excess of 0.25 MPa to increase the temperature of the system to a temperature in excess of 100 Deg. C for a period of time sufficient to achieve a sterile system, the dispersion system having micro- or nano-dispersions of small particles or droplets, the small particles or droplets having a stable state and an unstable state; and withdrawing pressure from the dispersion system of small particles or droplets before the particles or droplets reach the unstable state, wherein the particles or droplets comprise (i) a therapeutically active compound and (ii) an excipient, the excipient being associated with the therapeutically active compound, wherein the excipient comprises a surfactant.

    Ex-vivo application of solid microparticulate therapeutic agents
    50.
    发明专利
    Ex-vivo application of solid microparticulate therapeutic agents 未知

    公开(公告)号：ZA200610078B

    公开(公告)日：2008-06-25

    申请号：ZA200610078

    申请日：2006-12-01

    Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

    Inventor： KIPP JAMES E ,  RABINOW BARRETT E

    IPC: A61K20090101 ,  A61K9/14 ,  A61K35/12 ,  A61K45/00 ,  A61K47/48 ,  A61K49/00 ,  C12N20090101 ,  C12N5/06

    Abstract: The present invention is concerned with a method of preparing and delivering small particles of a pharmaceutically active material to a mammalian subject for treating diseases or disorders. A preferred embodiment entails: (i) the collection of tissue cells from an animal donor, (ii) selective or non-selective growth of these cells in a cell culture medium to which is added solid particles of a therapeutically active compound, mostly free of a drug carrier (about 10% or less, by weight), and having an average particle size of less than about 100 microns, (iii) contacting the cells in the cell culture medium with the solid particles of therapeutically active compound causing the particles to be taken up by the cells into either the intracellular compartment of the cultured cells, attachment of the active compound as particles to the periphery of such cells, or a combination of intracellular uptake and attachment to the cell surface, (iv) optionally, isolation and/or resuspension of the cells prepared in steps i through iii, (v) administering the cells to the mammalian subject. The pharmaceutically active material can be administered intravenously, intramuscularly, subcutaneously, intradermally, intra-articularly, intrathecally, epidurally, intracerebrally, via buccal route, rectally, topically, transdermally, orally, intranasally, via pulmonary route, intraperitoneally, or combinations thereof. After administration, the loaded cells transport the pharmaceutical composition as particles.

Patent Agency Ranking